Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription factor 7-like 1 (TCF7L1) is a member of the T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) family of transcription factors and encodes a high-mobility group (HMG) box protein involved in mediating Wnt/β-catenin signaling[2][4]. TCF7L1 predominantly functions as a transcriptional repressor but can act as an activator in the presence of β-catenin, regulating key processes such as cellular differentiation (notably in adipogenesis, epidermal development, and pituitary formation), cell cycle progression, and cellular senescence[1][2][3][4]. Genetic studies have linked TCF7L1 to type 2 diabetes, cancer, developmental defects, and neurodevelopmental disorders, highlighting its diverse and critical regulatory functions. TCF7L1 modulates target gene expression by direct DNA binding and recruitment of chromatin-modifying enzymes, and acts as a molecular hub integrating cell signaling pathways relevant for development and disease[1][3][4].
Modulation of Wnt signaling through transcriptional repression or activation (dependent on β-catenin interaction) Recruitment of chromatin-modifying enzymes (e.g., HDAC1) for gene silencing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription factor 7-like 1 (TCF7L1).